MULTIPLE MYELOMA REFRACTORY
Clinical trials for MULTIPLE MYELOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA REFRACTORY trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR T-Cell therapy aims to control Hard-to-Treat multiple myeloma
Disease control Not yet recruitingThis early-stage study tests a new treatment called S103 for people with multiple myeloma that has returned or stopped responding to standard therapies. S103 uses a patient's own immune cells, modified to target and attack the cancer. The main goals are to check safety and find t…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated May 26, 2026 07:44 UTC
-
Can a booster shot make CAR-T last longer in myeloma?
Disease control Not yet recruitingThis study tests whether adding a drug called NT-I7 (IL-7) after standard CAR-T therapy can help the immune cells stay active longer and control multiple myeloma better. About 52 adults whose myeloma has returned or not responded to treatment will receive either NT-I7 or a placeb…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
New CAR-T therapy targets two proteins to fight Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase study tests a new type of cell therapy (CAR-T) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It is for people whose multiple myeloma has come back or stopped responding to treatment. The main goals are to check safety and find the right dose in 12…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 26, 2026 07:22 UTC
-
Curcumin gets a makeover: new liposomal form tested in blood cancer
Disease control Not yet recruitingThis early-phase study tests the safety of a new form of curcumin (liposomal curcumin) in people with multiple myeloma that has returned or stopped responding to treatment. About 20 participants will receive the drug, with doses increasing in later groups to find the highest safe…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 22, 2026 13:54 UTC